Clinical trial
SU6668 in Treating Patients With Advanced Solid Tumors
NCT00024206 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00024206 |
|---|---|
| Title | SU6668 in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Surrogate Endpoint Trial of SU6668 in Patients With Incurable Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | orantinib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 12 |
| Start date | Jul 1, 2001 |
| Primary completion | Jul 1, 2003 |
| First posted | Oct 21, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: